2Baldi F. Lansoprazole ora-dispersible tablet :pharmacokinetics and therapeutic use in acid-ralated disorders. Drugs,2005,65:1419-1426.
3Andersson T, Hss RK, Bredberg E,et al. Pharmacokinetics and pharmacodynamics of esomeprazole,the S-isomer of omeprazole. Aliment Pharmacol Ther,2001,15 : 1563-1559.
4Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers. Digestion ,2003,68:184-188.
5Li XQ, Andersso TB,Ahlstrom M,et al. Comparison of inhibitory effects of the proton pump-inhibitory drugs omeprazole, asomeprazole, lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities. DMD,2004,32:821-827.
6Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg,pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms, Eur J Clin Pharmacol, 2004,60 : 531 - 539.
7Takahashi S, Yamazaki T, Okabe S. Leminoprazole protects cultured gastric mucosal cells against damage caused by ethanol, indometacin and taurocholate. Pharmacology, 1997,54 : 118-126.
8Takahashi S, Okabe S. Mechanism by which orally administered leminoprazole stimulates mucus synthesis in rats. Pharmacology, 1998,57:47-56.
9Galmiche JP, Broley Des Varannes S, et al. Tenatoprazole, a novel proton pump inhibitor with a rolonged plasma half-life:effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther,2004,19:655-662.
10Galmiche JP, Saeher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther,2005,21:575-582.
